Cara Therapeutics Inc. (CARA)

16.64 +0.02 (+0.12%)

IEX Real-Time Price

June 20, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 16.62

Price Open 16.71

Volume: 501,210

Avg Volume: 1.56M

Market Cap: 563.68M

P/E Ratio -10.34

52 Wk Range 11.11-28.5



CARA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-05-31
32.31M
6.84M
3.87
21.16%

2018-05-15
31.13M
7.25M
14.85
23.28%

2018-04-30
31.13M
7.65M
15.27
24.59%

2018-04-13
31.12M
7.51M
8.89
24.13%




CARA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-09
Q1 2018
AMC
-0.47 (5)
-0.51
-0.04

2018-05-03
Q1 2018
N/A
-0.40 (4)
0.00
0.00

2018-03-15
Q4 2017
AMC
-0.42 (3)
-0.43
-0.01

2018-03-08
Q4 2017
N/A
-0.39 (3)
-0.43
-0.01

News

Weekly Cannabis Report: Legalization Is Here, What's Next? (2018-06-11 14:28 SeekingAlpha)

Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Summary Last week, the widely-tracked Horizons Marijuana Life Sciences Index ETF ( OTC:HMLSF ) was higher by more than 6% and ended the week at $18.90.Hor…

 


Statistics

Shares Outstanding: 33.87M

Top 15 Institution Percent: 36.60

Price To Sales: N/A

Price To Book: 7.95

Revenue: N/A

Gross Profit: N/A

Cash: 215.42M

Debt: N/A

Return On Assets: -80.60

Return On Equity: -99.44

Profit Margin: N/A

Price History

Beta: 3.05

50-day Moving Avg: 13.86

200-day Moving Avg: 13.29

YTD Change: 29.44

5-day Change: -1.42

1-month Change: 42.05

3-month Change: 38.04

6-month Change: 34.03

1-year Change: -4.81

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Cara Therapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.